Short-term survival rates better for US vs. Canadian heart failure patients

November 28, 2005

Investigators at Yale School of Medicine and the Institute for Clinical Evaluative Sciences, Ontario, Canada, report that elderly heart failure patients hospitalized in the United States have better short-term survival than those in Canada, but lose that advantage over time.

Published in the November 28 issue of Archives of Internal Medicine, the study compared the patterns of care and outcomes of 28,521 Medicare patients with 8,180 similarly aged patients hospitalized in Canada. Compared to Canadian patients, those in the U.S. had almost a 20 percent lower risk of dying within 30 days of being hospitalized for heart failure, but by one year there was virtually no difference in the survival rates.

"Despite being based on the same medical literature, the health care systems in the United States and Canada have very different results with respect to patients with heart failure," said principal investigator Harlan M. Krumholz, M.D., professor of medicine at Yale and director of Yale-New Haven Hospital Center for Outcomes Research and Evaluation. "The findings raise questions about whether the American system is poised to provide better acute care, whereas the Canadian system is better positioned to provide chronic care."

Dennis Ko, M.D., lead author of the article and assistant professor, University of Toronto, said there are several potential explanations for our results. "The Canadian system has a greater emphasis on primary care and all patients have health insurance, including a drug benefit. It is possible that our approach leads to better patient follow-up and fewer financial barriers to care."

The study also showed that patients hospitalized in the United States were more likely to undergo tests and procedures, but just as likely to receive medications.

"Both systems can likely improve, but the American system may want to focus attention on outpatient care whereas the Canadian system may want to examine their inpatient care more closely," said Krumholz. "There is no reason for the different outcomes among patients in the United States and Canada except that they receive care in systems that are organized differently," We can take advantage of this natural experiment to learn how best to configure an optimal health care delivery system that puts our patients in the best position to do well in the short and long run."
-end-
Other authors on the study included Jack V. Tu, M.D., Frederick A. Masoudi, M.D., Yongfei Wang, Edward P. Havraneck, M.D., Saif S. Rathore, Alice M. Newman, Linda R. Donovan, Douglas S. Lee, M.D., and JoAnne M. Foody, M.D.

Citation: Archives of Internal Medicine, Vol. 165, 2486-2492 (November 28, 2005).

Yale University

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.